Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

Bibliographic Details
Main Authors:	Paul K. Keith, Juthaporn Cowan, Amin Kanani, Harold Kim, Gina Lacuesta, Jason K. Lee, Jie Chen, Michelle Park, André Gladiator
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	Allergy, Asthma & Clinical Immunology
Online Access:	https://doi.org/10.1186/s13223-023-00805-3

Similar Items

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
by: Paul K. Keith, et al.
Published: (2022-08-01)

Cutaquig<sup>®</sup> Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
by: Sydney Brownlee, et al.
Published: (2022-11-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss
by: Pınar Gür-Çetinkaya, et al.
Published: (2018-06-01)

Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
by: Scheuerlein, P, et al.
Published: (2018)

Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly)
by: Dorothea Grosse-Kreul, et al.
Published: (2024-10-01)

Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry.
by: Armin Abadeh, et al.
Published: (2023-01-01)

Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry
by: Armin Abadeh, et al.
Published: (2023-01-01)

Patient-centered outcomes with subcutaneous immunoglobulin use for infection control in primary and secondary immunodeficiencies: data of a GEIE Spanish Registry
by: Sandra Martínez Mercader, et al.
Published: (2025-02-01)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
by: R. Mallick, et al.
Published: (2020-08-01)

The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency
by: Selime Özen Bölük, et al.
Published: (2023-06-01)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
by: Martin Adriana, et al.
Published: (2012-11-01)

Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies – impact of drug packaging and administration method on patient reported outcomes
by: R. Mallick, et al.
Published: (2024-02-01)

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017-01-01)

Secondary Immunodeficiency
by: Persia Pourshahnazari, et al.
Published: (2025-01-01)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
by: Kristin Epland, et al.
Published: (2022-09-01)

Subcutaneous immunoglobulin-induced eczematous dermatitis
by: Rachel Breidbart, BS, et al.
Published: (2025-02-01)

Immunoglobulin replacement therapy for primary immunodeficiencies.
by: Peter, J, et al.
Published: (2014)

Subcutaneous immunoglobulin replacement therapy: the European experience.
by: Chapel, H, et al.
Published: (2013)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies
by: Roger H. Kobayashi, et al.
Published: (2022-12-01)

Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction
by: Rajiv Mallick, et al.
Published: (2025-01-01)

Levels of immunoglobulin isotypes in serum and respiratory samples of patients with chronic obstructive pulmonary disease: protocol for a systematic review and meta-analysis
by: Beverley Shea, et al.
Published: (2023-02-01)

Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients
by: Nicolò Compagno, et al.
Published: (2014-06-01)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
by: Parwinder K. Gill, et al.
Published: (2018-08-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Economic impact of immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer: a single center observational study
by: Luciana del Campo Guerola, et al.
Published: (2024-06-01)

Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases
by: Lina Laguado, et al.
Published: (2018-06-01)

Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?
by: Coco R. Beudeker, et al.
Published: (2022-10-01)

Assessment of local adverse reactions to subcutaneous immunoglobulin (SCIG) in clinical trials
by: Ballow, M, et al.
Published: (2017)

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
by: Bjorkander, J, et al.
Published: (2000)

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
by: Cherin Patrick, et al.
Published: (2014-01-01)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
by: Andrea Visentin, et al.
Published: (2022-12-01)

High-dose immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
by: Satomi Hiya, et al.
Published: (2022-06-01)

P1611: INSIGHTS INTO FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: FINAL RESULTS FROM THE FIGARO STUDY
by: M. Dimou, et al.
Published: (2022-06-01)

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita.
by: Tayal, U, et al.
Published: (2008)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
by: Patrick Cherin, et al.
Published: (2015-01-01)

Subcutaneous Immunoglobulin (SCig) for Maintenance Therapy in Severe POTS: A Case Report.
by: Tahrima Ferdous
Published: (2023-12-01)

Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
by: Patrick Cherin, et al.
Published: (2015-11-01)

Chorea secondary to human immunodeficiency virus infection
by: André Eduardo de Almeida Franzoi, et al.
Published: (2023-09-01)

Secondary immunodeficiency in lymphoproliferative malignancies.
by: Friman, V, et al.
Published: (2016)